All In Biotech

Drug Trial Radar · NCT02564497

A Study to Compare the Pharmacokinetics of Belatacept Using Active Pharmaceutical Ingredient Manufactured by Process E Relative to Process C

A Randomized, Open-label, Parallel-group, Single-dose, Biocomparability Study of the Pharmacokinetics of Belatacept Drug Products Using Active Pharmaceutical Ingredient Manufactured by Process E Relative to Active Pharmaceutical Ingredient Manufactured by Process C in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Apr 17, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 491 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

491

Actual

Start

Oct 2, 2015

Primary completion

Jan 27, 2017

Study completion Jan 27, 2017

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Sep 30, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Other
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of the study is to compare the Pharmacokinetics (PK) of Process E belatacept relative to Process C belatacept in Healthy subjects

Conditions

  • Renal Transplantation

Interventions

  • Process E BelataceptBiological

  • Process C BelataceptBiological

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area Under the Serum Concentration-time Curve From Time Zero Extrapolated to Infinite Time (INF) of Belatacept.Time frame: Day 1 to Day 71
  2. Maximum Observed Serum Concentration (Cmax) of BelataceptTime frame: Day 1 to Day 71

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • PPD Development

    Austin, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.